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Abstract 
Diffuse pulmonary hemorrhage (DPH) is an uncommon, acute
condition characterized by a variable combination of hemoptysis,
dyspnoea, anemia, hypoxemia, and an initial nonspecific imaging
features such as diffuse and bilateral ground glass pulmonary
opacities that can be induced by different causes. DPH is a rare
manifestation of adverse drug reactions. We report here the case of
a 25-year-old woman that has been admitted to our pulmonary
clinic for the onset of chest pain, cough and haemoptysis, started
one week after her first treatment with alemtuzumab for multiple
sclerosis. Computed tomography (CT) scan of the chest at the
admission showed diffuse and bilateral ground glass pulmonary
opacities. Her symptoms resolved completely without any
treatment, after the interruption of alemtuzumab, and a CT scan of
the chest performed one month later showed total disappearance of
the pulmonary opacities.
Introduction
Diffuse pulmonary hemorrhage (DPH) is a clinical syndrome
resulting from the accumulation of erythrocytes into the alveolar
space as a result of injury to the microcirculation of the lung [1,2];
it is characterized by a variable combination of hemoptysis,
dyspnoea, anemia, hypoxemia and an initial nonspecific imaging
features such as diffuse and bilateral ground glass pulmonary
opacities [3]. It can be induced by different causes, including
adverse reaction to several drugs (Table 1).
Alemtuzumab is a humanized, rat monoclonal immunoglobulin
(Ig) G1 antibody with a molecular weight of ~150 kDa, anti-cluster
of differentiation 52 (CD52) [4], a membrane glycoprotein
expressed on T and B lymphocytes, natural killer cells, monocytes,
macrophages, dendritic cells, and eosinophilic granulocytes. CD52
is involved in T lymphocyte co-stimulation, induction of regulatory
T lymphocytes, and T lymphocyte migration and adhesion [5].
Alemtuzumab causes a rapid depletion of circulating T and B
lymphocytes, as well as various cells of the innate immune system,
for this reason, it is used for the treatment of patients with active
relapsing-remitting multiple sclerosis [6]. 
Case Report
We present here the case of a 25-year-old Caucasian woman
(height 161 cm, weight 45 Kg, body mass index 17.4 Kg/m²), who
has been admitted to our pulmonary clinic from the emergency
ward of our hospital, in September 2018, for the acute onset of chest
pain, dyspnoea at rest, cough and non massive haemoptysis (<10
mL) [7], started after the fourth dose of alemtuzumab (intravenous
injection of 12 mg once daily) administered for a relapse of multiple
sclerosis. Alemtuzumab was administered for the first time on the
13rd September of 2018, followed by other three doses, respectively
on 14th, 16th, and 17th September of 2018. After her 3rd dose of the
treatment, mild erythema appeared in the upper limbs and the trunk
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required treatment with oral histamine 1 receptor antagonist
(intravenous injection of chlorphenamine 10 mg). She stopped the
treatment with alemtuzumab at the occurrence of the pulmonary
symptoms. 
She was unemployed, a non-smoker and had a medical history
of epilepsy (diagnosed in May 2015) secondary to the presence of
a cavernous angioma of the left frontal lobe that has been treated in
2015 with local embolization, and then followed by a regular
therapy with levetiracetam (500 mg once daily). In January 2017
she has been diagnosed multiple sclerosis, after performing, in
October 2016, a somatosensory evoked potential test (showed an
altered nerve impulse propagation along central somatosensory
pathways), and in November 2016 a spine magnetic resonance
imaging scan (showing demyelinating lesions in the white dorsal
and cervical spinal cord).
At the admission in our clinic, her vital signs were: systemic
blood pressure 120/85 mmHg, pulse frequency 80/min (rhythmic),
body axillary temperature 36.8°C, oxygen pulse oximetry value of
98% (when breathing room air) with a respiratory rate of 22 breaths
per min. Physical examination was normal. Computed tomography
(CT) scan of the chest showed diffuse and bilateral ground glass
pulmonary opacities, without pleural effusions (Figure 1A). During
her hospitalization, the routine laboratory examinations showed a
mild reduction of serum haemoglobin value of 13.5 g/dL, compared
to the last available value of 14.6 g/dL referred to the 11th June of
2018 obtained from patient’s past medical records. A mild increase
of the serum C-reactive protein value (2.27 mg/dL, normal values
<0.5 mg/dL) was also reported. The diffusing capacity for carbon
monoxide (Figure 2A), performed on the 4th day after
hospitalization, showed a normal value when corrected for actual
hemoglobin level (85% of the predicted value). The intradermal
reaction to purified protein derivative skin test was negative. The
search for serum IgG and IgM antibodies anti-Mycoplasma
pneumoniae, Chlamydophila pneumoniae, and Epstein-Barr virus
were negative; as well as the urinary Legionella pneumophila and
Pneumococcal antigens; and the serum and urine research of DNA
of Cytomegalovirus was negative. An echocardiogram was normal
with a systolic ejection fraction of 60% and a normal value of
systemic pulmonary arterial pressure. An ear, nose and throat
examination with endoscopy of the upper airways did not show any
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Table 1. List of drugs inducing DPH.
Antiplatelet agents
Abciximab, cilostazol, clopidogrel, epoprostenol, epifibatide, ticagrelor, ticlopidine, tirofiban
Anticoagulants and thrombolytic drugs
Apixaban, alteplase, brodifacoum, dabigatran, edoxaban, enoxaparin, rivaroxaban, streptokinase
Nonsteroidal anti-inflammatory and other anti-inflammatory drugs
Acetylsalicylic acid, azathioprine, ketorolac, oxyphenbutazone, paracetamol, penicillamine, systemic corticosteroids
Anti-infective drugs
Azithromycin, itraconazole, levamisole, metronidazole, moxalactam, nitrofurantoin, quinine
Antiarrhythmic and antihypertensive drugs
Amiodarone, hydralazine, ivabradine, quinidine
Antithyroid and other endocrinological drugs
Aminoglutethimide, clomiphene, ergometrine, methimazole, propylthiouracil
Oncological drugs
All-transretinoic acid, arsenic trioxide, bartezomib, carfilzomib, crizotinib, cyclophosphamide, cytarabine, docetaxel, erlotinib, etoposide, everolimus, fludara-










Ginkgo, ginseng, makyo-kanseki-to, sho seiryu-to, seisin-renshi-in
Other drugs
Benzbromarone, chlorphenamine, hyaluronic acid, lipiodol, montelukast, sevoflurane, sildenafil










lesion, and an infectivology consultation did not recommend any
antibiotic therapy. The patient refused to perform bronchoscopy
with bronchoalveolar lavage. 
She was left untreated and no other episodes of haemoptysis
occurred during her hospitalization. The patient was discharged at
home after nine days. After one month she returned to our outpatient
clinic for a post-discharge visit and performed a test to evaluate the
diffusion capacity for carbon monoxide (Figure 2B), that showed a
normal value (119% of the predicted value). A new CT scan of the
chest, performed on the 20th October 2018, showed the complete
resolution of the pulmonary opacities (Figure 1B). All these data
made us lean towards a diagnosis of diffuse pulmonary hemorrhage.
Discussion
DPH is a complex syndrome that may represent a diagnostic
and therapeutic challenge, with potentially significant morbidity and
mortality. For this reason, the identification of the underlying cause
of DPH with the initiation of appropriate treatment, whenever
possible, is essential for improving prognosis [8,9]. Imaging features
of DPH depend on its temporal evolution. At presentation, chest
imaging is normal in 20%-50% of cases. When present initial
radiographic findings consist of patchy ground glass opacities with
a central and basilar predominance and sparing the costophrenic
angles. The subacute phase (within 48 h) is generally characterized
by developing of interlobular and intralobular interstitial
thicknening associated with the persistence of ground glass opacities
by configuring the crazy-paving pattern on chest computed
tomography. When DPH is chronic and recurrent, pulmonary
fibrosis develops with regions of architectural distortion and areas
of lobular sparing [1]. DPH can be clinically categorized into
vasculitis, pulmonary-renal syndromes, autoimmune diseases, drug-
induced, and idiopathic. Drug-induced DPH imaging is typically
characterized by diffuse bilateral ground-glass opacities in the acute
setting with identification at the medical history of a clear cause-
effect relationship [1].
Laboratory findings during DPH often demonstrate anemia,
leukocytosis, levels elevated erythrocyte sedimentation rate and
serum C reactive protein; however, the absence of these findings
does not exclude DPH. Moreover, initial laboratory data typically
show anemia especially in patients with subacute or chronic
bleeding instead of acute bleeding as in our case [1, 3]. Increased
uptake of carbon monoxide may classically help in the diagnosis
of DPH when recent (48–72 hours), especially when combined
with a restrictive pattern. The diffusing capacity for carbon
monoxide in our patient was within normal value when corrected
for actual hemoglobin level. The diffusing capacity for carbon
monoxide is not a reliable diagnostic tool, often it cannot be
performed in the acute settings, and it requires repetitive
measurement for confirmation because of a wide normal range
[10]. In January 2020 a National Drug Authority (AIFA) note
introduced for alemtuzumab new therapeutic limitations and
                          [Monaldi Archives for Chest Disease 2020; 90:1352]                                          [page 475]
                             Case Report
Figure 1. A) Chest computed tomography scan at the hospital admission showing diffuse and bilateral ground-glass pulmonary opaci-
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contraindications, for the retrieving of severe adverse reactions,
sometimes fatal [11].
In our patient DPH as manifestation of drug effect may be
higher on the list of diagnostic considerations at the light of the
imaging findings and their temporal evolution with their resolution
one month after drug withdrawal. We performed a careful
differential diagnostic approach, with alemtuzumab resulting the
most likely cause of her DPH. The only other drug administered
was chlorphenamine, and no adverse pulmonary reactions are
reported in the product information of AIFA or MicroMedex
database, while only 4 cases of pulmonary haemorrhage are reported
in Vigibase [12]. 
The mechanisms of drug induced DPH are heterogeneous
including autoimmune or hypersensitivity reactions, or direct damage
of the alveolar epithelium or of its basement membrane [13]. The
mechanism by which alemtuzumab causes DPH is unknown. We
performed a search of some database of suspected adverse drug
reactions in VigiBase, the World Health Organization’s database [12],
and we found record of 16,517 cases of adverse alemtuzumab
reactions, of which 27 of pulmonary alveolar haemorrhage, 20 of
pulmonary haemorrhage and 5 of diffuse alveolar damage; while the
European Medicines Agency database, Eudravigilance [14], reported
7072 adverse alemtuzumab reactions cases, of which 4 of diffuse
alveolar haemorrhage, 17 of pulmonary alveolar haemorrhage and 12
of pulmonary haemorrhage. According to Naranjo causality
assessment scale [15] the causal relationship between use of
alemtuzumab and DPH was scored as “probable”.
Two cases of alemtuzumab associated diffuse alveolar
hemorrhage (DAH) in patients with multiple sclerosis have been
previously reported in literature [16,17]. As in our report, they were
two young women that developed acute dyspnoea, chest pain and
haemoptysis during first cycle of alemtuzumab 12 mg; body
temperature, blood pressure and heart rate were normal; laboratory
routine examination showed normal values. In Myro case report
[16], the patient showed an increased value of serum C reactive
protein (2.6 mg/dL) as our patient, and haemoglobin fell from 12
g/dL to 10.5 g/dL after the administration of alemtuzumab. In both
cases, CT scan of the chest showed diffuse and bilateral ground
glass pulmonary opacities with centrilobular distribution. In Myro
case [16] no treatment was given, and the symptoms resolved
spontaneously in two days, while in Bianco report [17], the patient
was treated with methylprednisolone IV 1000 mg/day. In both
patients CT performed after hospitalization showed total resolution
of pulmonary opacities.
Conclusions
Despite the mechanism by which alemtuzumab causes DPH is
unknown, we suggest to all the clinicians prescribing alemtuzumab
to consider DPH as a potential complication of this treatment.
Imaging maintains a central role in arriving at the diagnosis of DPH
considering distinguishing features and their temporal evolution. 
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